Realigned the field-based biomedical technician team to focus on smaller, more profitable client engagements rather than high-volume, low-return contracts.Strengthened the balance sheet by reducing net debt by 30% year-over-year while simultaneously returning capital through the repurchase of 1.3 million shares.Achieved a record quarterly adjusted EBITDA margin of 24.3%, driven by improved labor efficiency in biomedical services and a favorable shift toward higher-margin oncology revenue.Restructured the co ...